Form 4: BioMarin Pharmaceutical Executive Sells Shares
SEC Form 4 Filing
Charles Greg Guyer, EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., sold 7,034 shares of common stock on March 6, 2025.
Summary
- On March 6, 2025, Charles Greg Guyer, the EVP and Chief Technical Officer of BioMarin Pharmaceutical Inc., sold 7,034 shares of the company's common stock.
- The sale was executed at a weighted average price of $71.276 per share, with prices ranging from $71.276 to $71.285.
- Following the transaction, Guyer directly owns 87,655 shares of BioMarin Pharmaceutical Inc.
- The transaction was reported on a Form 4 filing with the SEC on March 7, 2025.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an executive stock sale. The size of the sale is relatively small compared to the executive's holdings.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. It is difficult to assess the impact of this sale without more context.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the impact is likely to be minimal given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of stock sale transaction |
| 03/07/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.